Drug Development

PBT-3 caused long-term growth inhibition of K562 solid tumors in vivo

Published in Cancer Weekly, January 24th, 2006

Researchers claimed PBT-3 caused long-term growth inhibition of K562 solid tumors.

"We demonstrate herein that daily administration of PBT-3 for 8 days to NU/NU mice bearing solid tumors derived from the s.c. administration of the leukemic cell line K562 results in inhibition of growth of the tumors in vivo, and this inhibition lasts for 60 days after stopping treatment with PBT-3 before recovery of tumor growth is reestablished," scientists reported in the journal Biochemical and Biophysical Research Communications.

"Similar findings were observed when the mice were treated with Gleevec (STI-571)," added X. Li and colleagues, Hospital for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-01-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry